Kraig Biocraft Laboratories (KBLB) Equity Average (2016 - 2022)
Kraig Biocraft Laboratories (KBLB) has disclosed Equity Average for 9 consecutive years, with -$3.8 million as the latest value for Q3 2022.
- Quarterly Equity Average rose 30.75% to -$3.8 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$3.8 million through Sep 2022, up 30.75% year-over-year, with the annual reading at -$3.9 million for FY2018, 36.58% down from the prior year.
- Equity Average hit -$3.8 million in Q3 2022 for Kraig Biocraft Laboratories, up from -$3.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of -$3.5 million in Q1 2018 to a low of -$5.9 million in Q2 2021.
- Historically, Equity Average has averaged -$4.5 million across 4 years, with a median of -$4.1 million in 2018.
- Biggest five-year swings in Equity Average: crashed 37.91% in 2018 and later surged 33.77% in 2022.
- Year by year, Equity Average stood at -$4.2 million in 2018, then dropped by 2.91% to -$4.3 million in 2019, then fell by 29.12% to -$5.6 million in 2021, then skyrocketed by 32.48% to -$3.8 million in 2022.
- Business Quant data shows Equity Average for KBLB at -$3.8 million in Q3 2022, -$3.9 million in Q2 2022, and -$4.7 million in Q1 2022.